Medicamen Organics Ltd (MEDIORG) is currently trading at 24.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Medicamen Organics Limited is a WHO/GMP certified Indian pharmaceutical company that develops, manufactures and distributes a broad portfolio of 84 generic dosage forms — tablets, capsules, liquids, ointments and powders — primarily as a contract/third‑party manufacturer from two Haridwar facilities, serving government and private institutional clients domestically and via export distributors internationally. In FY2026 the company recorded a sharp operating swing: consolidated revenue fell about 41% year‑on‑year to ₹22.71 crore and the group moved to a consolidated net loss (PBT) of ₹5.28 crore, reversing the prior year profit; the decline reflects weaker sales, elevated expenses and one‑off write‑offs that materially compressed cash and profitability. The company recently completed strategic corporate moves: an IPO (₹10.54 crore raised in 2024), a preferential warrants issue (~₹3.00 crore) and inorganic expansion with a 51% stake in Depot Pharmacy Yego Ltd (Rwanda) plus formation of Grande Etoile and Loire Cosmetics — signaling a clear push into African markets and branded product development internationally. Balance sheet and cash dynamics show stress: inventories and receivables remain elevated (inventories ~₹10.29 crore standalone, receivables ~₹17.97 crore standalone) while cash fell to ₹0.60 crore; management reallocated unutilized IPO proceeds to working capital after shareholder approval, and recorded significant write‑offs (GST refund ₹33.09 lakh, Nepal receivable ₹110 lakh). Operational and legal risks are material and disclosed: pending civil suits, tax and GST disputes, a large advance from a Rwandan customer stalled by regional conflict (₹40.21 lakh), and non‑provision for some demands create contingent exposure that could affect liquidity and recovery timelines.

Over the past 52 weeks, Medicamen Organics Ltd has traded between a low of ₹19.10 and a high of ₹37.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Medicamen Organics Ltd has a market capitalization of approximately 36.53. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Medicamen Organics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -9.09 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 36.53 Cr, Medicamen Organics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Medicamen Organics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Medicamen Organics Ltd is -9.09. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.